Tatva Chintan

Is Tatva Chintan overvalued or undervalued?

As of August 18, 2021, Tatva Chintan is considered overvalued with a PE ratio of 379.10, significantly higher than its peers, and despite short-term gains, it has a poor long-term performance with a 3-year return of -59.09%.

As of 18 August 2021, the valuation grade for Tatva Chintan moved from does not qualify to very expensive, indicating a significant shift in its perceived market value. The company is currently assessed as overvalued, with a PE ratio of 379.10, an EV to EBITDA ratio of 64.04, and a Price to Book Value of 2.94. These ratios suggest that the stock is trading at a premium compared to its earnings and book value, raising concerns about its sustainability at such high valuations.<BR><BR>In comparison to its peers, Tatva Chintan's valuation appears excessive, particularly when contrasted with Solar Industries India Ltd., which has a PE ratio of 123.77, and Godrej Industries Ltd., which is valued at a much more reasonable PE of 46.63. The stark differences in these ratios highlight the relative overvaluation of Tatva Chintan within the specialty chemicals sector. Furthermore, while the company has outperformed the Sensex in the short term, with a 1-month return of 30.59% compared to the Sensex's 3.81%, its long-term performance has been lackluster, with a 3-year return of -59.09%. This discrepancy reinforces the conclusion that Tatva Chintan is currently overvalued.

Has Tatva Chintan declared dividend?

Tatva Chintan Pharma Chem Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 6, 2024. Despite the dividend announcement, the company has experienced significant declines in price returns over various periods.

Tatva Chintan Pharma Chem Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 4.34%, the dividend return was 0%, resulting in a total return of 4.34%.<BR><BR>Over the past year, the price return was -8.59%, with a dividend return of 0.20%, leading to a total return of -8.39%.<BR><BR>In the last 2 years, the price return was -43.71%, while the dividend return was 0.23%, resulting in a total return of -43.48%.<BR><BR>For the 3-year period, the price return was -60.51%, the dividend return was 0.28%, culminating in a total return of -60.23%.<BR><BR>Over the last 4 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there was also no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Tatva Chintan has declared a dividend, the total returns over various periods indicate significant declines in price, suggesting challenges in the company's performance despite the dividend announcement.

Who are the peers of the Tatva Chintan?

Tatva Chintan's peers include DDev Plastiks, Fineotex Chem, Bhansali Engg., Jubilant Agri, Yasho Industries, Vidhi Specialty, Paushak, Excel Industries, Jyoti Resins, and Platinum Industr. In terms of management risk and growth, Tatva Chintan is rated average, with a 1-year return of -19.87%, better than DDev Plastiks but worse than Excel Industries, which has the highest return at 14.83%.

Peers: The peers of Tatva Chintan are DDev Plastiks, Fineotex Chem, Bhansali Engg., Jubilant Agri, Yasho Industries, Vidhi Specialty, Paushak, Excel Industries, Jyoti Resins, and Platinum Industr.<BR><BR>Quality Snapshot: Excellent management risk is observed at DDev Plastiks, Fineotex Chem, Bhansali Engg., Jubilant Agri, Yasho Industries, and Jyoti Resins, while Average management risk is found at Tatva Chintan, Vidhi Specialty, Paushak, Excel Industries, and Platinum Industr. Growth is rated as Excellent for Jubilant Agri and Jyoti Resins, Good for DDev Plastiks, while Average growth is seen in Fineotex Chem, and the rest. Below Average growth is noted for Tatva Chintan, Bhansali Engg., Yasho Industries, Vidhi Specialty, Paushak, and Excel Industries, with the rest having similar ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Excel Industries at 14.83%, while the lowest is DDev Plastiks at -27.62%, with Tatva Chintan's 1-year return at -19.87% being better than DDev Plastiks but worse than Excel Industries. Additionally, the six-month return is negative for DDev Plastiks, Fineotex Chem, Bhansali Engg., Yasho Industries, Vidhi Specialty, and Platinum Industr.

Who are in the management team of Tatva Chintan?

As of March 2022, the management team of Tatva Chintan includes Chintan Nitinkumar Shah (Chairman/Executive Director), Ajaykumar Mansukhlal Patel (WTD & Executive Director), Shekhar Rasiklal Somani (WTD & Executive Director), and three Independent Non-Executive Directors: Subhash Patel, Avani Rajesh Umatt, and Manher Chinmanlal Desai.

As of March 2022, the management team of Tatva Chintan includes the following individuals:<BR><BR>1. Chintan Nitinkumar Shah - Chairman / Executive Director<BR>2. Ajaykumar Mansukhlal Patel - WTD & Executive Director<BR>3. Shekhar Rasiklal Somani - WTD & Executive Director<BR>4. Subhash Patel - Independent Non-Executive Director<BR>5. Avani Rajesh Umatt - Independent Non-Executive Director<BR>6. Manher Chinmanlal Desai - Independent Non-Executive Director<BR><BR>These members play various roles within the company's governance and management structure.

What does Tatva Chintan do?

Tatva Chintan Pharma Chem Ltd is a small-cap company in the specialty chemicals industry, incorporated in 1996 and publicly listed since January 2021, with recent net sales of ₹1,079 Cr and a net profit of ₹10 Cr as of March 2025. Key metrics include a P/E ratio of 388.00 and a market cap of ₹2,216 Cr.

Overview:<BR>Tatva Chintan Pharma Chem Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 1996 as 'Tatva Chintan Pharma Chem Private Limited' and transitioned to a public limited company on 27 January 2021. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,079 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 10 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 2,216 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 388.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.21%<BR>- Debt-Equity: 0.03<BR>- Return on Equity: 0.77%<BR>- Price to Book: 2.97<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

Who are the top shareholders of the Tatva Chintan?

The top shareholders of Tatva Chintan include Shekhar Rasiklal Somani with 23.07%, two mutual fund schemes with 5.34%, 15 foreign institutional investors holding 3.3%, and Nippon Life India Trustee Ltd at 3.31%, while individual investors account for 16.92%.

The top shareholders of Tatva Chintan include the promoters, with Shekhar Rasiklal Somani holding the highest stake at 23.07%. There are also two mutual fund schemes that collectively hold 5.34%, and 15 foreign institutional investors (FIIs) with a combined holding of 3.3%. Additionally, the highest public shareholder is Nippon Life India Trustee Ltd, which holds 3.31%. Individual investors account for 16.92% of the shareholding.

How big is Tatva Chintan?

As of 24th July, Tatva Chintan Pharma Chem Ltd has a market capitalization of 2,297.00 Cr, with recent net sales of 382.71 Cr and a net profit of 5.72 Cr. Shareholder's funds are 737.08 Cr, and total assets amount to 806.42 Cr as of March 2024.

As of 24th July, Tatva Chintan Pharma Chem Ltd has a market capitalization of 2,297.00 Cr, which classifies it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 382.71 Cr and a Net Profit of 5.72 Cr.<BR><BR>The latest annual reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 737.08 Cr and Total Assets of 806.42 Cr.

Is Tatva Chintan technically bullish or bearish?

As of 14 October 2025, Tatva Chintan's technical trend is bullish, supported by strong daily moving averages and positive Bollinger Bands and OBV, although caution is advised due to mildly bearish signals from the MACD and KST on the weekly chart.

As of 14 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, with strength indicated by daily moving averages and positive performance in the Bollinger Bands and OBV on both weekly and monthly time frames. However, the MACD and KST on the weekly show mildly bearish signals, which suggests some caution. Overall, the bullish indicators outweigh the bearish ones, supporting a positive outlook for Tatva Chintan in the specialty chemicals industry.

How has been the historical performance of Tatva Chintan?

Tatva Chintan's historical performance has shown significant volatility, with net sales and profits declining from 2022 to 2025, while total assets and liabilities increased. Key metrics include a drop in profit after tax from INR 95.87 crore in March 2022 to INR 5.71 crore in March 2025.

Answer:<BR>The historical performance of Tatva Chintan shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tatva Chintan's net sales have seen a decline from INR 423.61 crore in March 2023 to INR 382.71 crore in March 2025, with a peak of INR 433.65 crore in March 2022. Total operating income followed a similar trend, decreasing to INR 382.71 crore in March 2025 from INR 423.61 crore in March 2023. The company's operating profit (PBDIT) also dropped significantly from INR 117.26 crore in March 2022 to INR 36.53 crore in March 2025. Profit before tax decreased from INR 104.12 crore in March 2022 to INR 7.58 crore in March 2025, while profit after tax fell from INR 95.87 crore in March 2022 to INR 5.71 crore in March 2025. The earnings per share (EPS) reflected this decline, dropping from INR 43.24 in March 2022 to INR 2.44 in March 2025. On the balance sheet, total assets increased from INR 649.59 crore in March 2022 to INR 823.62 crore in March 2025, while total liabilities also rose from INR 649.59 crore to INR 823.62 crore in the same period. Cash flow from operating activities decreased from INR 98 crore in March 2024 to INR 24 crore in March 2025, and the company experienced a net cash outflow of INR 23 crore in March 2025. Overall, Tatva Chintan's financial performance has shown significant volatility, particularly in profitability metrics, while total assets and liabilities have increased.

When is the next results date for Tatva Chintan Pharma Chem Ltd?

The next results date for Tatva Chintan Pharma Chem Ltd is 16 May 2026.

The next results date for Tatva Chintan Pharma Chem Ltd is scheduled for 16 May 2026.

Are Tatva Chintan Pharma Chem Ltd latest results good or bad?

Tatva Chintan Pharma Chem Ltd's latest results show a significant year-on-year net profit increase of 901.94% and a 24.36% revenue growth, indicating recovery; however, there was a 31.97% decline in net profit quarter-on-quarter due to a high tax rate, raising concerns about sustainable profitability despite operational momentum.

Tatva Chintan Pharma Chem Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year increase in net profit, soaring by 901.94% to ₹10.32 crores in Q4 FY26. This reflects a recovery from a challenging previous year. Additionally, revenue grew by 24.36% year-on-year, reaching ₹134.14 crores, marking the highest level in at least eight quarters.<BR><BR>However, the quarter-on-quarter performance reveals a concerning decline, with net profit dropping by 31.97% from ₹15.17 crores in Q3 FY26. This decline was primarily attributed to an unusually high effective tax rate of 37.79%, which significantly impacted profitability. Moreover, while operating margins improved to 20.97%, they remain below the levels seen in previous quarters.<BR><BR>The company has demonstrated operational momentum with seven consecutive quarters of revenue growth, but the volatility in profit margins and the low return on equity of 5.83% compared to industry peers raises questions about sustainable profitability. Overall, while there are positive signs of recovery, the recent results also highlight significant challenges that need to be addressed for long-term stability and growth.

Should I buy, sell or hold Tatva Chintan Pharma Chem Ltd?

Which are the latest news on Tatva Chintan?

Why is Tatva Chintan Pharma Chem Ltd falling/rising?

As of 18-May, Tatva Chintan Pharma Chem Ltd's stock price is currently at 1,253.80, reflecting a decline of 4.44% and significant volatility. Despite positive quarterly results, the stock has underperformed recently, with a year-to-date drop of 6.20%.

As of 18-May, Tatva Chintan Pharma Chem Ltd's stock price is falling, currently at 1,253.80, which reflects a decrease of 58.2 points or 4.44%. This decline is evident in today's performance, where the stock has underperformed its sector by 5.3% and has experienced a trend reversal after two consecutive days of gains. The stock reached an intraday low of Rs 1205, marking an 8.16% drop at its lowest point.<BR><BR>In terms of volatility, the stock has shown high fluctuations today, with an intraday volatility of 5.74%. Additionally, while the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, indicating a short-term weakness.<BR><BR>Despite the company reporting positive results in recent quarters, including a growth in net sales of 2.14% and the highest quarterly net sales at Rs 134.14 crore, the stock's performance over the past week has been negative, with a decrease of 5.97%. Year-to-date, the stock has also fallen by 6.20%, contrasting with its strong performance over the past year, where it generated a return of 62.83% compared to the Sensex's decline of 8.52%. <BR><BR>Overall, the combination of today's significant drop, high volatility, and recent underperformance against the sector contributes to the current falling trend of Tatva Chintan Pharma Chem Ltd's stock price.